September 13, 2021
The Food and Drug Administration announced an upcoming virtual meeting of the Blood Products Advisory Committee (BPAC) that will take place from 9:30 a.m. to 5:20 p.m. ET on Thursday, Nov. 4. This meeting marks the first for BPAC since the beginning of the COVID-19 public health emergency.
The Committee will meet in open session via an online teleconferencing platform to hear an overview from the research programs of the Plasma Derivatives Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research (CBER). The agenda also includes updates from the Laboratory of Cellular Hematology, Division of Blood Components and Devices, Office of Blood Research and Review (OBRR), CBER; and the Laboratory of Emerging Pathogens, Division of Emerging & Transfusion Transmitted Diseases, OBRR, CBER. Following each of the three topics, the meeting will be closed to the public to “permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy.
Individuals with questions may contact email@example.com.